Seminars in Hematology
Volume 44 , Pages S2-S6 , July 2007

Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin’s Lymphoma

  • Fernando Cabanillas

      Affiliations

    • Corresponding Author InformationAddress correspondence to Fernando Cabanillas, MD, Hospital Auxilio Mutuo, Avenida Ponce de Leon #725, Parada 37-1/2, San Juan, Puerto Rico 00919.

References 

  1. Hodgkin T. On some morbid appearances of the absorbent gland and spleen. Med-Chi Trans. 1832;17:68–114
  2. Hancock BW. Early clinical pathologists. 2. Thomas Hodgkin: Pathologist, physician, and philanthropist. J Clin Pathol. 1990;43:616–618
  3. Sutcliffe SB, Gospodarowicz MK, Fitzpatrick PJ. In memoriam: Vera Peters. J Clin Oncol. 1994;12:239–240
  4. World Health Organization Classification of Tumours. Pathology and Genetidcs of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001;
  5. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007;
  6. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma (The Non-Hodgkin’s Lymphoma Classification Project). Blood. 1997;89:3909–3918
  7. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes (Non-Hodgkin’s Lymphoma Classification Project). J Clin Oncol. 1998;16:2780–2795
  8. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475
  9. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol. 1993;20:75–88
  10. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–1459
  11. McLaughlin P, Fuller LM, Velasquez WS, et al. Stage I-II follicular lymphoma (Treatment results for 76 patients). Cancer. 1986;58:1596–1602
  12. López-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998;91:2955–2960
  13. Lee MS, Chang KS, Cabanillas F, et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science. 1987;237:175–178
  14. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262–1268
  15. Gribben JG, Freedman A, Woo SD, et al. All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 1991;78:3275–3280
  16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  17. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: A randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol. 2003;22:564;(abstr 2269)
  18. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582–1589
  19. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the natural history of follicular lymphoma. Blood. 2004;104:168a;(abstr 583)

PII: S0037-1963(07)00098-4

doi: 10.1053/j.seminhematol.2007.06.007

Seminars in Hematology
Volume 44 , Pages S2-S6 , July 2007

Article Tools

* Image Usage & Resolution